Evidence map›Paper›PMID 41277870›Full record

ArticlemBio2026

HIV-1 transcription dominates over host gene activity at the HIV-1 integration site.

Samuel Weissman, Yang-Hui J Yeh, Miriam Viazmenski, Rachel Kim, Jack A Collora, Savannah Steinhauser, Ya-Chi Ho

Abstract read
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samuel WeissmanDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-4377-1094
Yang-Hui J YehDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.
Miriam ViazmenskiDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.
Rachel KimDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.
Jack A ColloraDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.
Savannah SteinhauserDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.
Ya-Chi HoDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-7046-0147

Funding

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
CHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JOSEPH D PUGLISI · 2022 to 2026
$34.4M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
The Y-SCORCH Data Generation Center at Yale for Single-Cell Opioid Responses in the Context of HIVUM1DA051410 · NIDA · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, KLUGER, YUVAL · 2020 to 2025
$15.3M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Ya-Chi Ho, Jonathan Li · 2022 to 2026
$10.1M
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIVU01DA053628 · NIDA · YALE UNIVERSITY · PI HO, YA-CHI, SESTAN, NENAD · 2021 to 2025
$9.5M
Role of clonal expansion in HIV-1 persistenceR01AI141009 · NIAID · YALE UNIVERSITY · PI Ya-Chi Ho · 2018 to 2026
$5.3M
Predoctoral Training Program in VirologyT32AI055403 · NIAID · YALE UNIVERSITY · PI KUMAR, PRITI, MOTHES, WALTHER H · 2003 to 2024
$3.6M
Understanding HIV-1 persistence in cytotoxic CD4+ T lymphocytes at the single cell levelR01AI174863 · NIAID · YALE UNIVERSITY · PI Ya-Chi Ho · 2023 to 2026
$3.4M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
A Big Data Approach to Identify Epigenetic, Transcriptomic, and Network Dynamics as Immune Dysfunction Drivers Associated with HIV Infection and Substance Use DisorderR01DA051906 · NIDA · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER · 2020 to 2024
$2.8M
Understanding HIV-1 persistence and HIV-1-induced inflammation in tissuesR01AI183430 · NIAID · YALE UNIVERSITY · PI Ya-Chi Ho · 2024 to 2026
$2.6M
NIAID NIH HHS P01 AI169768NIAID NIH HHS R01 AI141009NIAID NIH HHS R01 AI174863NIAID NIH HHS R01 AI176601NIAID NIH HHS R01 AI183430NIAID NIH HHS T32 AI055403NIAID NIH HHS U54 AI170856NIAID NIH HHS UM1 AI164565NIAID NIH HHS UM1 AI164570NIDA NIH HHS R01 DA051906NIDA NIH HHS R33 DA047037NIDA NIH HHS U01 DA053628NIDA NIH HHS UM1 DA051410
6 · The paper itself

Abstract

Despite effective antiretroviral therapy (ART), HIV-1 persists as an integrated DNA provirus in the genome of infected cells. Host cells can regulate HIV-1 transcription at the HIV-1 integration site dependent on the location (actively transcribed genes vs repressive chromatin) and the orientation (in the same vs opposite orientation of the host gene transcription) of HIV-1 integration. Presumably, HIV-1 follows the host gene transcriptional activity at the HIV-1 integration site. We interrogated HIV-1-host gene transcriptional interactions at the HIV-1 integration site using CRISPR-mediated activation and inhibition of the host genes (in which HIV-1 was integrated) in seven HIV-1-infected Jurkat T cell clones with known HIV-1 integration sites in the introns of actively transcribed genes and a non-genic region. Using ATAC-seq and strand-specific RNA-seq to examine chromatin accessibility and RNA transcription levels, we found that host gene activation did not increase HIV-1 transcription, while host gene inhibition did not decrease HIV-1 transcription. HIV-1 drove high levels of aberrant host RNA transcription regardless of the HIV-1 integration orientation. HIV-1-driven aberrant host RNA transcription was inhibited by CRISPR-mediated HIV-1 inhibition but not by CRISPR-mediated host gene activation or inhibition. When HIV-1 was integrated into a non-genic region, HIV-1 increased host chromatin accessibility and drove high levels of aberrant host RNA transcription. Overall, HIV-1 LTR promoter-driven transcriptional activity dominated over the host promoter activity. HIV-1 transcription does not passively follow host gene activity. Our results highlight that despite effective ART, silencing HIV-1 promoter is required to inhibit HIV-1-driven aberrant host gene expression and chronic immune activation. IMPORTANCE: HIV-1 persists as an integrated provirus in infected cells. Antiretroviral therapy (ART) does not inhibit HIV-1 promoter activity. Therefore, despite effective ART, HIV-1 promoter continues to drive HIV-1 antigen expression and induce chronic immune activation. HIV-1 eradication relies on either effective HIV-1 latency reversal (the shock-and-kill strategy) or permanent HIV-1 silencing (the block-and-lock strategy). Therefore, understanding the transcriptional regulation of HIV-1 expression is key to HIV cure. Presumably, HIV-1 transcription passively follows host gene activity at the HIV-1 integration site. Using a CRISPR-mediated host gene activation and inhibition, we found that host gene activation does not increase HIV-1 transcription, while host gene repression does not inhibit HIV-1 transcription. HIV-1 drives aberrant host RNA expression even when HIV-1 is integrated into a non-genic region. Overall, HIV-1 dominates over host gene activity at the HIV-1 integration site. Despite ART, additional strategies silencing HIV-1 promoter activity are required to halt HIV-1-induced chronic immune activation.

Indexed as

HIV-1HIV InfectionsHost-Pathogen InteractionsTranscription, GeneticViral TranscriptionVirus IntegrationChromatinHumansJurkat CellsProvirusesChromatinCRISPR activation and inhibitionHIV-1 integration siteHIV cureinsertional mutagenesistranscriptional interference

Identifiers

PMID41277870
PMCPMC12802265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.